Adverse effects of intravenous immunoglobulin therapy

Clinical Pediatrics

Volumn 35, Issue 1, 1996, Pages 23-31

  Ryan, Michael E ^a   Webster, Michael L ^b   Statler, John D ^c  

^a GEISINGER MEDICAL CENTER   (United States)

^b AKRON CHILDREN'S HOSPITAL   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHISTAMINIC AGENT; IMMUNOGLOBULIN; PARACETAMOL; PETHIDINE; STEROID;

BLOOD TOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; REVIEW; SIDE EFFECT;

EID: 0030069525     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289603500105     Document Type: Review

References (62)

1. Stiehm ER. Recent progress in the use of intravenous immunoglobulin. Curr Probl Pediatr. 1992;22:335-348.
2. NIH Consensus: intravenous immunoglobulin; prevention and treatment of disease. JAMA. 1990;264:3189-3193.
3. Intravenous immunoglobulin use in children. Can Med Assoc J. 1992;146:121-124.
4. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med. 1991;325:110-117.
5. Intravenous immune globulin for the prevention of bacterial infections in children with asymptomatic human immunodeficiency virus infection [Abstract]. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. N Engl J Med. 1991;325:73-80.
6. Rousell RH, Dodkin MB, Budinger MD. Transmission of hepatitis after the administration of intravenous immunoglobulins. Am J Clin Pathol 1993;99:649.
7. Mitra G, Dobkin MB, Budinger MD, Lourie RE. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion. 1986;26: 394-397.
8. Dwyer JM. Intravenous therapy with gamma globulin. Adv Intern Med. 1987;32:111-135.
9. Miller KB, Scheunkein DP, Wasserman RL. Safety and tolerability of an intravenous immune globulin at various concentrations in 5% dextrose injection or sterile water for injection. Clin Pharm. 1992;11:7:628-31.
10. Ippoliti C, Williams LA, Huber S. Toxicity of rapidly infused concentrated intravenous immune globulin. Clin Pharm. 1992;11:1022-1026.
11. Rao SP, Teitlebaum J, Miller ST. Intravenous immune globulin and aseptic meningitis. Am J Dis Child. 1992;146: 539-540.
12. Pallares DE, Marshall GS. Acute aseptic meningitis associated with administration of intravenous immune globulin. Am J Ped Hematol Oncol. 1992;14:279.
13. Molina JM, Coffineau A, Rain JD, Letowturierr AM. Aseptic meningitis following administration of intravenous immune globulin. Clin Infect Dis. 1992;15:564-565.
14. Castells-Van Daele M, Wijndaele L, Hunnick K. Intravenous immune globulin and acute aseptic meningitis. N Engl J Med. 1990;323:614-615.
15. Kressebuch H, Schaad UB, Hurt A, Bianchetti MG. Cerebrospinal fluid inflammation induced by intravenous immunoglobulins. Pediatr Infect Dis J. 1992;11:894-895.
16. Meiner Z, Ben-Hur T, River Y, Reckes A. Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. J Nerurol Neurosurg Psychiatry. 1993,56:830-831.
17. Vera-Ramirez M, Charlet M, Parry CJ. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammation demyelinating polyradiculoneuropathy, Neurology. 1992;42:1636-1637.
18. Mitterer M, Pescosta N, Vogetseder W, et al. Two episodes of aseptic meningitis during intravenous immunoglobulin therapy of idiopathic thrombocytopenic purpura. Ann Hematol. 1993;67:151-152.
19. Hague RA, Eden OB, Yap PL, et al. Hyperviscosity in HIV infected children - a potential hazard during intravenous immunoglobulin therapy. Blut. 1990;61: 66-67. Abstract
20. Martin CM, Matlow AG, Chew E, et al. Hyperviscosity syndrome in a patient with acquired immunodeficiency syndrome. Arch Intern Med. 1989;149:1435-1436.
21. Gilbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257-258.
22. Schifferli J, Leski M, Favre HN, et al. Highdose intravenous IgG treatment and renal function. Lancet. 1991;337:457-458.
23. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1991;36:83-86.
24. Donatini B. Transient renal dysfunction in diabetic patients after IVIG therapy. J Intern Med. 1992;232:376.
25. Kobosko J, Nicol P. Renal toxicity of intravenous immunoglobulin. Clin Nephrol. 1992;37:216-217.
26. Phillips AO. Renal failure and intravenous immunoglobulin. Clin Nephrol. 1992;37:217.
27. Moran M, Kapsner C. Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med. 1987;317:150-152.
28. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol. 1993;50:137-139.
29. Barandun S. Replacement therapy in primary immunodeficiencies. In: Nydegger UE, Morrel A, eds, Clinical Uses of Intravenous Immunoglobulins. London, UK: Academic Press; 1986:63-67.
30. Comenzo R, Malachowski ME. Meissner HC, et al. Immune hemolysis. disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr. 1992;120:926-928.
31. Copelan EA, Strohm PL, Kennedy MS, Tutschk PJ. Hemolysis following intravenous immune globulin therapy. Transfusion. 1986;26:410-412.
32. Moscow JA, Casper AJ, Kodis C, Fricke WA. Positive direct antiglobulin test results after intravenous immune globulin administration. Transfusion. 1987; 27:248-249.
33. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983;2 (8343): 193-195.
34. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82.633-635.
35. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous gamma globulin. N Engl J Med. 1992; 326:270-271.
36. Lassiter HA, Bubb ICW. Bertolone SJ, et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Pediatr Hematol Oncol. 1993;15:120-123.
37. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2(8500):217-218.
38. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin. Lancet 1986;2(8504):468.
39. Lane RS, Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet. 1983;2(8356):974-975.
40. Webster ADB, Lever AML. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet. 1986;1 (8476):322-323.
41. Lever AML, Brown D, Webster ADB, Thomas HC Non-A, non-B hepatitis occurring in agammaglobulinemic patients after intravenous immunoglobulin. Lancet. 1984;2(8411):1062-1064.
42. Intravenous immune globulin. Med Lett Drug Ther. 1992;34:116-118.
43. Vallari DS, Jett BW, Alter HJ, et al. Serological markers of post-transfusion hepatius C viral infection. J Clin Microbiol. 1992;30:552-556.
44. Imbach P, Perret BA, Bobington R, et al. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang. 1991;61:240-243.
45. Rodell MB, Bergman GE. Safety of immune globulin preparations with regard to human immunodeficiency virus. J Infect Dis. 1990;162:997.
46. Sugitani M, Inchauspe G, Slundo M, Prince AM. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992;339.1018-1019.
47. Dodd RY. Hepatitis C virus, antibodies and infectivity. Paradox, pragmatism and policy. Am J Pathol. 1992;97:4-6. Editorial.
48. Yu MW, Masou BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet. 1995;345:1173-1174.
49. Nubling CM, Willkommen H, Lower J. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet. 1995;345:1174.
50. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globin. N Engl J Med. 1994; 331:1607-1611.
51. Iwarson S, Wejst'l R, Ruttimann E. NonA, non-B hepatitis associated with the administration of intravenous immunoglobulin transmission studies in chimpanzees. Serodiag Immunother. 1987;1: 261-266.
52. CDC. Outbreak of hepatitis C associated with intravenous immunoglobulin administration. United States, October 1993-June 1994. MMWR 1994;43:505-509.
53. Horowitz B, Prince AM, Horowitz MG, Watklevicz C. Viral safety of solvent-detergent treated blood products. Dev Biol Stand, 1993,81-147-161.
54. Taliane G, Guerra E, Rosso R, et al. Hepatitis C virus infection in hypogammaglobulinemic patients receing long-term replacement therapy with intravenous immunoglobulin. Transfusion. 1995;32:103-107.
55. Schiano TD, Bellary SV, Black M. Possible transmission of hepatitic C virus infection with intravenous immunoglobulin. Ann Intern Med. 1995;122:802-803.
56. Burks AW, Sampson HA, Buckler RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. N Engl J Med. 1986;314:560-564.
57. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion. Lancet. 1987;1 (8543):436.
58. Ayliffe W, Haeney M, Roberts SC, Lavin M. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Lancet. 1992;339:558-559.
59. Berkman SA, Lee ML, Hale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990;112:278-295.
60. Craig TJ, Davis W. Hepatitis associated with high-dose intravenous gamma-globulin. Ann Allergy. 1993;71:276.
61. Schiff RI, Buckley RH, Sedlak D. Rapid infusion of sandoglobulin (R) in patients with primary humoral immunodeficiency [Abstract]. In: Imbach P, ed. Immunotherapy with Intravenous Immunoglobulins. London, UK: Harcourt Brace Jovanovich; 1991:437-438.
62. Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am J Med. 1986;81:443-446.